Matthew Ros's Net Worth
$2.04 Million
Who is Matthew Ros?
Matthew Ros has an estimated net worth of $2.04 Million. This is based on reported shares across multiple companies, which include Cogent Biosciences, Inc., and Epizyme, Inc..
SEC CIK
Matthew Ros's CIK is 0001673802
Past Insider Trading and Trends
2020 was Matthew Ros's most active year for acquiring shares with 14 total transactions. Matthew Ros's most active month to acquire stocks was the month of May. 2020 was Matthew Ros's most active year for disposing of shares, totalling 10 transactions. Matthew Ros's most active month to dispose stocks was the month of May. 2018 saw Matthew Ros paying a total of $692,289.12 for 178,608 shares, this is the most they've acquired in one year. In 2020 Matthew Ros cashed out on 232,219 shares for a total of $2,540,651.97, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Cogent Biosciences, Inc. (COGT) Snapshot price: $10.47
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 26
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Epizyme, Inc. No price found
See RemarksMatthew Ros owns 111,313 units of Common stock, par value $0.0001, 3,122 units of Commons Stock, par value $0.0001 and 84,082 units of Common Stock. In the year 2016 Matthew Ros filed a total of 18 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +33.81% | 28.13K |
—
|
—
| 111.31K |
Aug 16
| |||
Form 4
| -1.06% | -894.00 |
$11.21 | -$10,021.74 | 83.19K |
Scheduled
|
Feb 4
| ||
Form 4
| +50.26% | 28.13K |
—
|
—
| 84.08K |
Feb 1
| |||
Form 4
| -4.88% | -2.87K |
$11.41 | -$32,769.52 | 55.96K |
Scheduled
|
Jan 25
| ||
Form 4
| +6.03% | 3.27K |
$16.15 | -$44,057.20 | 57.51K |
Scheduled
|
Jun 25 - Jun 26
| ||
Form 4/A
| +7.96% | 4K |
—
|
—
| 54.23K |
Mar 24
| |||
Form 4
|
—
|
0
|
$15.36 | -$1,317,774.46 | 51.8K |
Scheduled
|
Jun 18
| ||
Form 4
| +0.62% | 320 |
$15.28 | -$18,993.04 | 51.8K |
Scheduled
|
Mar 24 - Mar 25
| ||
Form 4
| +29.37% | 11.69K |
—
|
—
| 51.48K |
Feb 3
| |||
Form 4
| +1.94% | 758 |
$23.38 | -$99,158.08 | 39.79K |
Scheduled
|
Jan 23 - Jan 24
| ||
Form 4
| +7.77% | 2.81K |
$12.10 | -$14,338.50 | 39.03K |
Scheduled
|
Jun 12 - Jun 13
| ||
Form 4
| +989.89% | 32.89K |
—
|
—
| 36.22K |
Jan 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 9
| |||
Form 4
|
—
|
0
|
$13.25 | -$509,405.48 | 5.72K |
Scheduled
|
Feb 5
| ||
Form 4
|
∞
| 1.71K |
$6.21 | $10,612.66 | 1.71K |
Feb 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||